MedTrace Logo

Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients

NCT01770119 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-09-18

No results posted yet for this study

Summary

Measles is a vaccine-preventable disease, which can be life-threatening in immunosuppressed children. Currently, measles vaccine is not recommended in pediatric orthotopic liver transplant recipients, because it is a live-attenuated vaccine.

We want to assess the influence of immunosuppression on immunity against measles in previously vaccinated children and to evaluate the induction of B cell and T cell response against measles elicited by vaccination in children at least 12 months after transplantation.

Conditions

Interventions

BIOLOGICAL

MMR vaccination

Unprotected children will be vaccinated with two MMR vaccines

Sponsors & Collaborators

  • University Hospital, Geneva

    collaborator OTHER

  • Klara M. Pósfay Barbe

    lead OTHER

Principal Investigators

  • Klara M Posfay-Barbe, MD, MS · University Hospitals of Geneva

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2022-04-30
Completion
2025-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770119 on ClinicalTrials.gov